Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Press, R. D.
Right arrow Articles by Coull, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Press, R. D.
Right arrow Articles by Coull, B. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*Genetics Home Reference

(Stroke. 1996;27:44-48.)
© 1996 American Heart Association, Inc.


Articles

Ischemic Stroke in the Elderly

Role of the Common Factor V Mutation Causing Resistance to ActivatedProtein C

Richard D. Press, MD, PhD; Xiao-Yuan Liu, MD; Nancy Beamer, MS Bruce M. Coull, MD

From the Departments of Pathology (R.D.P., X.-Y.L.) and Neurology (N.B., B.M.C.), Oregon Health Sciences University, and the Veteran's Affairs Medical Center (N.B., B.M.C.), Portland, Ore.

Correspondence to Oregon Health Sciences University, Department of Pathology, Mail Code L113, 3181 SW Sam Jackson Park Rd, Portland, OR 97201-3098. E-mail pressr@ohsu.edu.

Background and Purpose A common missense mutation in coagulation factor V (Arg 506 Gln) creates phenotypic resistance to the anticoagulant effects of activated protein C and predisposes carriers to venous thrombosis. To assess a correlation between this common hypercoagulable state and ischemic cerebrovascular disease, we have compared the prevalence of this mutation in a group of stroke patients with that in several control patient groups.

Methods The presence of the factor V Arg 506 Gln mutation was determined by a direct polymerase chain reaction–based assay on peripheral blood leukocytes from 161 elderly patients with acute ischemic stroke, 116 elderly patients with stroke risk factors but without acute stroke, 54 healthy elderly control subjects, and 287 younger control individuals (197 blood donors and 90 neonates).

Results The prevalence of the heterozygous Arg 506 Gln factor V mutation was not significantly different in the elderly stroke patients (2.5%) compared with either of the age-matched control groups (2% to 4%). The prevalence of this mutation was significantly higher in each of two younger control groups ({approx}8%) than in the elderly stroke patients (2.5%).

Conclusions The common factor V Arg 506 Gln mutation predisposing to venous thrombosis is not a significant genetic risk factor for ischemic stroke in the elderly.


Key Words: blood coagulation • cerebrovascular disorders • mutation • risk factors • thrombosis




This article has been cited by other articles:


Home page
J Child NeurolHome page
S. Gokben, A. Tosun, N. Bayram, G. Serdaroglu, M. Polat, K. Kavakli, and H. Tekgul
Arterial Ischemic Stroke in Childhood: Risk Factors and Outcome in Old Versus New Era
J Child Neurol, October 1, 2007; 22(10): 1204 - 1208.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
N. Buyru, J. Altinisik, G. Somay, and T. Ulutin
Factor V Leiden Mutation in Cerebrovascular Disease
Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 339 - 342.
[Abstract] [PDF]


Home page
Arch NeurolHome page
J. P. Casas, A. D. Hingorani, L. E. Bautista, and P. Sharma
Meta-analysis of Genetic Studies in Ischemic Stroke: Thirty-two Genes Involving Approximately 18 000 Cases and 58 000 Controls
Arch Neurol, November 1, 2004; 61(11): 1652 - 1661.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Juul, A. Tybjarg-Hansen, R. Steffensen, S. Kofoed, G. Jensen, and B. G. Nordestgaard
Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses
Blood, June 17, 2002; 100(1): 3 - 10.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Strater, K. Kurnik, C. Heller, R. Schobess, P. Luigs, and U. Nowak-Gottl
Aspirin Versus Low-Dose Low-Molecular-Weight Heparin: Antithrombotic Therapy in Pediatric Ischemic Stroke Patients: A Prospective Follow-Up Study
Stroke, November 1, 2001; 32(11): 2554 - 2558.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
S. Lopaciuk, K. Bykowska, H. Kwiecinski, A. Mickielewicz, A. Czlcankawska, T. Mendel, A. Kuczynska-Zardzewialy, D. Szelagowska, J. Windyga, W. Schroder, et al.
Factor V Leiden, Prothrombin Gene G20210A Variant, and Methylenetetrahydrofolate Reductase C677T Genotype in Young Adults With Ischemic Stroke
Clinical and Applied Thrombosis/Hemostasis, October 1, 2001; 7(4): 346 - 350.
[Abstract] [PDF]


Home page
StrokeHome page
G. J. Hankey, J. W. Eikelboom, F. M. van Bockxmeer, E. Lofthouse, N. Staples, and R. I. Baker
Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes
Stroke, August 1, 2001; 32(8): 1793 - 1799.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
Y. Mira, J. Todoli, R. Alonso, M. L. Mico, A. Vaya, F. Ferrando, A. Estelles, P. Villa, and J. Aznar
Factor V Leiden and Prothrombin G20210A in Relation to Arterial and/or Vein Rethrombosis: Two Cases
Clinical and Applied Thrombosis/Hemostasis, July 1, 2001; 7(3): 234 - 237.
[Abstract] [PDF]


Home page
StrokeHome page
C. D. Bushnell and L. B. Goldstein
Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke
Stroke, December 1, 2000; 31(12): 3067 - 3078.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
I. Hisar, M. Ileri, E. Yetkin, R. Atak, K. Senen, F. Kosar, S. Dundar, and D. Demirkan
Role of Activated Protein C Resistance in Left Atrial Thrombogenesis in Patients with Mitral Stenosis
Angiology, October 1, 2000; 51(10): 855 - 860.
[Abstract] [PDF]


Home page
BrainHome page
A. Hassan and H. S. Markus
Genetics and ischaemic stroke
Brain, September 1, 2000; 123(9): 1784 - 1812.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
U. Nowak-Gottl, R. Strater, A. Heinecke, R. Junker, H.-G. Koch, G. Schuierer, and A. von Eckardstein
Lipoprotein (a) and Genetic Polymorphisms of Clotting Factor V, Prothrombin, and Methylenetetrahydrofolate Reductase Are Risk Factors of Spontaneous Ischemic Stroke in Childhood
Blood, December 1, 1999; 94(11): 3678 - 3682.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Kenet, J. Freedman, B. Shenkman, E. Regina, F. Brok-Simoni, F. Holzman, F. Vavva, N. Brand, A. Michelson, M. Trolliet, et al.
Plasma Glutathione Peroxidase Deficiency and Platelet Insensitivity to Nitric Oxide in Children With Familial Stroke
Arterioscler. Thromb. Vasc. Biol., August 1, 1999; 19(8): 2017 - 2023.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Margaglione, G. D'Andrea, N. Giuliani, V. Brancaccio, D. De Lucia, E. Grandone, V. De Stefano, P. A. Tonali, and G. Di Minno
Inherited Prothrombotic Conditions and Premature Ischemic Stroke : Sex Difference in the Association With Factor V Leiden
Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1751 - 1756.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Kiechl, A. Muigg, P. Santer, M. Mitterer, G. Egger, M. Oberhollenzer, F. Oberhollenzer, A. Mayr, A. Gasperi, W. Poewe, et al.
Poor Response to Activated Protein C as a Prominent Risk Predictor of Advanced Atherosclerosis and Arterial Disease
Circulation, February 9, 1999; 99(5): 614 - 619.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
V Ganesan, M A McShane, R Liesner, J Cookson, I Hann, and F J Kirkham
Inherited prothrombotic states and ischaemic stroke in childhood
J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 508 - 511.
[Abstract] [Full Text]


Home page
Arch NeurolHome page
J. F. Meschia, J. Biller, T. Witt, A. Greist, and S. N. Rhinehart
Is Hormone Replacement a Risk Factor for Ischemic Stroke in Women With Factor V Leiden Mutation?
Arch Neurol, August 1, 1998; 55(8): 1137 - 1139.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Serena, T. Segura, M. J. Perez-Ayuso, J. Bassaganyas, A. Molins, and A. Davalos
The Need to Quantify Right-to-Left Shunt in Acute Ischemic Stroke : A Case-Control Study
Stroke, July 1, 1998; 29(7): 1322 - 1328.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
W. T. Longstreth Jr, F. R. Rosendaal, D. S. Siscovick, H. L. Vos, S. M. Schwartz, B. M. Psaty, T. E. Raghunathan, T. D. Koepsell, and P. H. Reitsma
Risk of Stroke in Young Women and Two Prothrombotic Mutations: Factor V Leiden and Prothrombin Gene Variant (G20210A)
Stroke, March 1, 1998; 29(3): 577 - 580.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
H. S Markus and H. Hambley
Neurology and the blood: haematological abnormalities in ischaemic stroke
J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 150 - 159.
[Full Text] [PDF]


Home page
ANGIOLOGYHome page
G. Orlandi, A. Pellegrinetti, C. Fioretti, A. Martini, and L. Murri
Factor V Leiden Mutation in a Case with Ischemic Stroke: which Relationship?: A Case Report
Angiology, January 1, 1998; 49(1): 79 - 82.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
B. Zoller, A. Hillarp, and B. Dahlback
State-of-the-Art Review: Activated Protein C Resistance: Clinical Implications
Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 25 - 32.
[Abstract] [PDF]


Home page
StrokeHome page
R. L. Brey and B. M. Coull
Cerebral Venous Thrombosis: Role of Activated Protein C Resistance and Factor V Gene Mutation
Stroke, October 1, 1996; 27(10): 1719 - 1720.
[Full Text]


Home page
StrokeHome page
M. Fisher, J. A. Fernandez, S. F. Ameriso, D. Xie, A. Gruber, A. Paganini-Hill, and J. H. Griffin
Activated Protein C Resistance in Ischemic Stroke Not Due to Factor V Arginine506->Glutamine Mutation
Stroke, July 1, 1996; 27(7): 1163 - 1166.
[Abstract] [Full Text]